LTD₄/CysLT₁

Leukotriene D4 (LTD4) is a potent pro-inflammatory mediator that signals primarily through the CysLT1 receptor, regulating cellular proliferation and inflammatory responses^[1]. Mechanistically, LTD4 binding to CysLT1 triggers intracellular calcium mobilization and activation of downstream signaling pathways, including ERK, CREB, and β-catenin, which collectively promote cell growth and gene transcription^[1][2]. In airway models, CysLT1 activation by LTD4 contributes to bronchial smooth muscle hyperplasia and airway hyperresponsiveness, effects that are enhanced by cytokines such as TGF-β and IL-13 but not IL-4, highlighting receptor expression modulation under inflammatory conditions^[3][4][5]. Compared with the closely related CysLT2 receptor, CysLT1 demonstrates distinct ligand specificity and pharmacological profiles, as selective antagonists like Montelukast efficiently block LTD4-induced responses without substantially affecting CysLT2-mediated signaling^[6][1]. In disease contexts, CysLT1 engagement by LTD4 promotes eosinophil infiltration, airway remodeling, and tumor cell migration, making it relevant in asthma, chronic rhinosinusitis, and cancer metastasis^[7][8][9]. For experimental applications, selective CysLT1 antagonists allow precise modulation of LTD4 signaling, enabling studies on receptor-dependent proliferation, cytokine interactions, and inflammatory mediator production^[3][6][1].